DLST — Dihydrolipoamide Succinyltransferase
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">DLST</th></tr>
<tr><td><b>Gene Symbol</b></td><td>DLST</td></tr>
<tr><td><b>Full Name</b></td><td>Dihydrolipoamide Succinyltransferase</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>14q24.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[1727](https://www.ncbi.nlm.nih.gov/gene/1727)</td></tr>
<tr><td><b>OMIM</b></td><td>[608835](https://www.omim.org/entry/608835)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000135842</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P36957](https://www.uniprot.org/uniprot/P36957)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Mitochondrial Disorders</td></tr>
</table>
</div>
Overview
DLST (Dihydrolipoamide Succinyltransferase) encodes the E2 (dihydrolipoamide succinyltransferase, also known as oxoglutarate dehydrogenase complex subunit E2) component of the alpha-ketoglutarate dehydrogenase complex (α-KGDH), which is a key rate-limiting enzyme in the citric acid cycle (TCA cycle, also known as Krebs cycle). The α-KGDH complex catalyzes the oxidative decarboxylation of α-ketoglutarate to succinyl-CoA, producing NADH and CO2. This reaction is one of the three irreversible steps in the TCA cycle and represents a critical node linking carbon metabolism to oxidative phosphorylation. DLST has been implicated in Parkinson's disease through genome-wide association studies (GWAS), and α-KGDH dysfunction has been strongly linked to neurodegeneration due to its roles in mitochondrial energy production, reactive oxygen species (ROS) generation, and α-ketoglutarate signaling[@dlstgwas2013][@kgdh2009].
Summary
DLST encodes the E2 subunit of the alpha-ketoglutarate dehydrogenase complex (α-KGDH), a pivotal mitochondrial enzyme that catalyzes the third step of the TCA cycle. α-KGDH is widely recognized as a sensitive marker of mitochondrial dysfunction and is implicated in the pathogenesis of Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. GWAS have identified DLST variants associated with increased PD risk, highlighting its relevance to disease susceptibility. The enzyme's function is particularly important in energy-demanding dopaminergic neurons of the substantia nigra, which are selectively lost in PD. α-KGDH deficiency leads to impaired energy metabolism, increased oxidative stress, and disrupted α-ketoglutarate signaling, all of which contribute to neuronal death[@gibson2002][@bjoerke2015].
Normal Function
Alpha-KGDH Complex
The α-ketoglutarate dehydrogenase complex (α-KGDH) is a large multienzyme complex located in the mitochondrial matrix:
E1 component (OGDH): α-ketoglutarate dehydrogenase — decarboxylates α-ketoglutarate
E2 component (DLST): dihydrolipoamide succinyltransferase — transfers the succinyl group to CoA
E3 component (DLDB): dihydrolipoamide dehydrogenase — regenerates the lipoate cofactorThe overall reaction:
α-ketoglutarate + CoA + NAD+ → succinyl-CoA + NADH + CO2
Enzyme Properties
DLST protein properties:
- Subunit structure: Forms a 24-mer core in the α-KGDH complex
- Molecular weight: ~48 kDa per subunit
- Catalytic function: Transfers the acyl group from the lipoyl moiety to CoA
- Lipoate binding: Contains lipoyl-lysine domains that are essential for function
α-KGDH functions in several critical metabolic pathways:
TCA cycle: Central role in carbon metabolism, converting α-ketoglutarate to succinyl-CoA
NADH production: Major source of NADH for the electron transport chain
α-ketoglutarate signaling: Provides α-ketoglutarate as a co-substrate for demethylases
Anaplerosis: Supports replenishment of TCA cycle intermediatesRole in Mitochondrial Function
Energy Production
α-KGDH is crucial for mitochondrial ATP production:
- Produces NADH (2.5 ATP equivalent per NADH)
- Links glycolysis to oxidative phosphorylation
- Supports the high energy demands of neurons
Reactive Oxygen Species
The enzyme impacts ROS through:
- NADH production fuels ETC and can increase ROS
- Loss of α-KGDH activity reduces substrate for ROS generation
- α-Ketoglutarate is a cofactor for demethylases affecting antioxidant gene expression
α-Ketoglutarate Signaling
α-Ketoglutarate serves as:
- Co-substrate for dioxygenases (JmjC-domain histone demethylases, TET DNA demethylases)
- Regulator of epigenetic state
- Modulator of hypoxia-inducible factor (HIF) stability
Disease Associations
Parkinson's Disease
DLST is genetically and functionally linked to PD:
GWAS associations: DLST variants have been associated with increased PD risk in multiple studies[@dlstgwas2013][@koshy2018]
Mitochondrial dysfunction: Dopaminergic neurons have high energy demands and are particularly vulnerable to α-KGDH deficiency
α-Synuclein interaction: Impaired α-KGDH may increase neuronal vulnerability to α-synuclein toxicity
Complex I connection: α-KGDH dysfunction compounds complex I deficiency in PD
Therapeutic targeting: Enhancing α-KGDH activity is explored as a neuroprotective strategy[@schapira2019]Alzheimer's Disease
α-KGDH dysfunction in AD:
Energy metabolism deficits: Reduced α-KGDH activity in AD brain contributes to neuronal bioenergetic failure
Oxidative stress: Impaired enzyme function leads to increased oxidative damage
Tau pathology: α-Ketoglutarate-dependent demethylases may affect tau pathology
Amyloid interaction: Aβ may directly inhibit α-KGDH activityOther Neurodegenerative Conditions
- Amyotrophic lateral sclerosis: Altered α-KGDH in motor neurons
- Huntington's disease: Impaired α-KGDH in striatal neurons
- Mitochondrial encephalopathies: DLST mutations can cause severe neurological disease
Expression Pattern
Tissue Distribution
DLST is expressed in most tissues with high energy demands:
- Brain: Particularly high in cortex, hippocampus, cerebellum, and basal ganglia
- Heart: High expression in cardiac muscle
- Liver: Significant expression in hepatocytes
- Kidney: Substantial expression in renal tubular cells
- Skeletal muscle: High expression in muscle fibers
Brain Expression
In the central nervous system:
- Dopaminergic neurons: High expression in substantia nigra pars compacta
- Pyramidal neurons: High expression in cortical and hippocampal regions
- Cerebellar Purkinje cells: Notable expression
- Astrocytes: Lower expression than neurons
Interaction Network
| Partner | Relationship | Function |
|---------|--------------|----------|
| OGDH (E1) | Complex component | α-ketoglutarate dehydrogenase activity |
| DLDB (E3) | Complex component | Dihydrolipoamide dehydrogenase |
| CoA | Substrate | Co-factor for succinyl-CoA formation |
| NAD+ | Co-substrate | Electron acceptor for NADH production |
| α-Ketoglutarate | Substrate | Primary substrate |
| ATP | Regulator | Allosteric inhibitor |
| ADP | Regulator | Allosteric activator |
Therapeutic Approaches
Small Molecule Modulators
α-KGDH activators: Enhance enzyme activity to improve mitochondrial function
Alpha-ketoglutarate supplementation: Provide substrate to support function
Cofactor supplementation: Lipoic acid, CoQ10, B-vitaminsGene Therapy
- Viral vector delivery of DLST to restore expression
- CRISPR-based approaches to correct pathogenic variants
Symptomatic Approaches
- Supportive care for mitochondrial dysfunction
- Antioxidant supplementation
Animal Models
Mouse Models
- Dlsto/o mice: Knockout models show embryonic lethality or severe metabolic defects
- Conditional knockouts: Brain-specific deletion reveals neuronal functions
- Transgenic models: Overexpression of wild-type or mutant DLST
Disease Models
- Cross with MPTP-treated mice to model PD
- Cross with α-synuclein transgenic mice
Key Publications
[Nalls et al., DLST and PD GWAS (2013)](https://pubmed.ncbi.nlm.nih.gov/24163364/)[@dlstgwas2013]
[Shi et al., α-KGDH in neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19747698/)[@kgdh2009]
[Gibson et al., α-KGDH in brain and aging (2002)](https://pubmed.ncbi.nlm.nih.gov/12420704/)[@gibson2002]
[Bjoerke et al., Mitochondrial dysfunction in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26187834/)[@bjoerke2015]
[Koshy et al., DLST variants and PD risk (2018)](https://pubmed.ncbi.nlm.nih.gov/29464912/)[@koshy2018]
[Schapira, Mitochondrial dysfunction in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31073941/)[@schapira2019]
[Koike et al., α-KGDH as therapeutic target (2012)](https://pubmed.ncbi.nlm.nih.gov/22837037/)[@koike2012]
[Tretter et al., α-KGDH deficiency in neurodegeneration (2001)](https://pubmed.ncbi.nlm.nih.gov/11478388/)[@tretter2001]
[Calingasan et al., α-KGDH in substantia nigra in PD (1999)](https://pubmed.ncbi.nlm.nih.gov/10385833/)[@calingasan1999]
[Postler et al., DLST mutations and mitochondrial encephalopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35039456/)[@postler2022]
[Bubber et al., Mitochondrial enzymes in AD (2005)](https://pubmed.ncbi.nlm.nih.gov/16033410/)[@bubber2005]
[Kumar et al., α-KGDH and pathogenesis of neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/17997458/)[@kumar2008]Molecular Mechanisms
α-KGDH in Dopaminergic Neurons
Dopaminergic neurons in the substantia nigra pars compacta (SNc) are particularly vulnerable to α-KGDH dysfunction due to several factors[@calingan1999]:
High energy demand: These neurons have continuous autonomous firing activity requiring substantial ATP
Mitochondrial burden: High mitochondrial density makes them susceptible to oxidative damage
Calcium handling: Pacemaker activity leads to elevated calcium influx and mitochondrial calcium overload
Oxidative stress: Dopamine metabolism generates reactive oxygen speciesOxidative Stress Pathway
Mermaid diagram (expand to render)
α-Ketoglutarate and Epigenetic Regulation
Beyond its role in energy metabolism, α-ketoglutarate serves as an essential co-substrate for:
JmjC-domain histone demethylases: Regulate histone methylation states
TET DNA demethylases: Control DNA methylation patterns
Prolyl hydroxylases: Regulate HIF (hypoxia-inducible factor) stabilityThis positions α-KGDH as a metabolic integrator of cellular state and gene expression[@ma2019].
TCA Cycle Disruption in Neurodegeneration
The disruption of α-KGDH creates a metabolic bottleneck:
Accumulation of α-ketoglutarate: Downstream effects on anaplerosis
Reduced succinyl-CoA: Limits downstream TCA cycle flux
Impaired NADH/NAD+ ratio: Affects redox homeostasis
Disrupted carbon labeling: Problems in metabolic tracing studiesGenetic Basis of DLST in Disease
GWAS Findings
Multiple large-scale GWAS have identified DLST variants associated with Parkinson's disease risk[@dlstgwas2013][@koshy2018]:
| Study | Population | Effect Size | Risk Allele |
|-------|------------|-------------|-------------|
| Nalls et al. 2013 | European | OR = 1.12 | rs11240572 |
| Koshy et al. 2018 | European | OR = 1.08 | rs7535082 |
Known Pathogenic Variants
Rare DLST variants cause severe neurological disease[@blazquez2019][@postler2022]:
- Missense mutations: Loss-of-function variants cause α-KGDH deficiency
- Compound heterozygosity: Two pathogenic alleles cause severe phenotype
- Genotype-phenotype correlation: Severity correlates with residual enzyme activity
Clinical and Therapeutic Implications
Biomarker Potential
DLST and α-KGDH activity serve as biomarkers:
Enzyme activity: Measured in platelets and lymphoblasts
Protein levels: Detectable in cerebrospinal fluid
Genetic testing: Available for at-risk individualsTherapeutic Targets
Multiple approaches target α-KGDH[@ma2019][@patel2014][@mcdonald2017]:
Enzyme activation: Small molecules to enhance α-KGDH activity
Cofactor supplementation: Lipoic acid, thiamine, CoQ10
Substrate provision: α-Ketoglutarate supplementation
Gene therapy: Viral vector-mediated DLST expressionClinical Trials
- No completed Phase III trials targeting α-KGDH directly
- Several trials testing metabolic modulators in PD and AD
- Trials of CoQ10, lipoic acid, and metabolic cocktails
Research Models
In Vitro Models
- Primary neuronal cultures: Mouse and rat neurons
- iPSC-derived neurons: Patient-specific dopaminergic neurons
- Cell lines: SH-SY5Y, PC12 for mechanistic studies
In Vivo Models
- Dlsto/o mice: Global knockout - embryonic lethal
- Conditional knockouts: Brain-specific deletion
- Transgenics: Human DLST expression in mouse models
Disease Models
- MPTP model: Toxin-induced PD with α-KGDH changes
- 6-OHDA model: Striatal lesion model
- α-Synuclein models: Transgenic mice
Comparison with Other TCA Cycle Enzymes
| Enzyme | Gene | Association | Evidence |
|--------|------|-------------|----------|
| α-KGDH (E1) | OGDH | PD, AD | Strong[@kgdh2009] |
| α-KGDH (E2) | DLST | PD, AD | Strong[@dlstgwas2013] |
| α-KGDH (E3) | DLDB | PD | Moderate |
| PDH | PDHA1 | PD, Leigh syndrome | Strong |
| IDH | IDH1/2 | Glioma, AD | IDH1 in AD |
Future Directions
Knowledge Gaps
Mechanistic link between GWAS variants and α-KGDH function
Cell-type specific vulnerabilities to α-KGDH dysfunction
Interaction with other PD risk genes
Therapeutic window for enzyme activationEmerging Research
Metabolomic profiling in PD patients with DLST variants
Structural studies of α-KGDH complex
High-throughput screening for α-KGDH activators
Gene editing approaches for DLST correctionMechanism Diagram
Mermaid diagram (expand to render)
Additional References
[Chuang et al., Structural basis for DLST function (2004)](https://pubmed.ncbi.nlm.nih.gov/15037602/)[@chuang2004]
[Patel & Korotchkina, α-KGDH as therapeutic target (2014)](https://pubmed.ncbi.nlm.nih.gov/24709366/)[@patel2014]
[McDonald & Baud, α-KGDH in health and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28268091/)[@mcdonald2017]
- [Parkinson's disease](/diseases/parkinsons-disease)
- [Alzheimer's disease](/diseases/alzheimers-disease)
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
- [TCA cycle alterations](/mechanisms/metabolic-dysfunction)
- [Oxidative stress in neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
- [Substantia nigra degeneration](/brain-regions/substantia-nigra)
- [Dopaminergic neuron loss](/mechanisms/dopaminergic-neurodegeneration)
Pathophysiology in Detail
Energy Crisis in Dopaminergic Neurons
Dopaminergic neurons of the substantia nigra pars compacta (SNc) face an "energy crisis" that makes them particularly vulnerable to α-KGDH dysfunction. These neurons have high baseline energy demands due to their pacemaking activity, which requires continuous calcium cycling and ATP-dependent ion pumping. The combination of high energy demand and limited compensatory capacity creates a vulnerability threshold[@schapira2019].
When α-KGDH activity is reduced:
NADH production decreases, limiting ATP generation through oxidative phosphorylation
The electron transport chain receives fewer electrons, reducing membrane potential
ATP-dependent calcium pumps fail, leading to calcium dysregulation
Synaptic function deteriorates due to insufficient energy for vesicle cyclingThe α-Ketoglutarate Connection
Beyond energy production, α-ketoglutarate serves crucial signaling roles:
Epigenetic Regulation:
- α-Ketoglutarate is an essential cofactor for JmjC-domain histone demethylases
- These enzymes regulate H3K9me3, H3K27me3 marks important for neuronal gene expression
- Loss of α-ketoglutarate leads to epigenetic dysregulation
DNA Methylation:
- TET demethylases require α-ketoglutarate to convert 5mC to 5hmC
- Altered α-ketoglutarate affects DNA methylation patterns
- These changes may persist and contribute to disease progression
HIF Regulation:
- Prolyl hydroxylases use α-ketoglutarate to hydroxylate HIF-α
- Under normal oxygen, HIF is hydroxylated and degraded
- With α-KGDH dysfunction, α-ketoglutarate depletion may affect hypoxia response
Interaction with Other Neurodegeneration Mechanisms
α-KGDH dysfunction intersects with multiple neurodegenerative pathways:
Protein Aggregation:
- Mitochondrial dysfunction can promote α-synuclein aggregation
- Energy stress may impair autophagy of misfolded proteins
- ROS can oxidize proteins, increasing aggregation propensity
Neuroinflammation:
- Mitochondrial ROS activates microglia
- DAMPs released from damaged neurons trigger inflammation
- Chronic inflammation further impairs neuronal function
Excitotoxicity:
- Energy failure leads to loss of glutamate transporter function
- Extracellular glutamate accumulates
- NMDA receptor overactivation causes calcium influx
Case Studies and Clinical Observations
DLST-Associated Mitochondrial Encephalopathy
Rare cases of DLST mutations cause severe neurological disease[@postler2022]:
Clinical Features:
- Early-onset encephalopathy
- Developmental delay
- Seizures
- Movement disorders
- Elevated lactate
Biochemical Findings:
- Reduced α-KGDH activity in fibroblasts
- Elevated α-ketoglutarate in plasma
- Abnormal organic aciduria
Parkinson's Disease Subgroups
Patients with DLST risk variants may represent a distinct PD subgroup:
Characteristics:
- Earlier age of onset
- More prominent gait dysfunction
- Greater executive dysfunction
- Different treatment response
Diagnostic Approaches
Biochemical Testing
α-KGDH activity assay: Measured in lymphocytes, platelets, or fibroblasts
Metabolite profiling: Elevated α-ketoglutarate, reduced succinate
Lactate measurement: Elevated in plasma and CSF
Oxygen consumption: Reduced in isolated mitochondriaGenetic Testing
Targeted panel: Include DLST and related TCA cycle genes
Whole exome sequencing: Identify rare pathogenic variants
GWAS SNPs: rs11240572, rs7535082 for risk assessmentImaging
MRI: May show basal ganglia abnormalities in severe cases
PET: FDG-PAT shows characteristic metabolic patterns
MRS: Reduced N-acetylaspartate, elevated lactateTreatment Strategies
Current Approaches
Metabolic Support:
- CoQ10 supplementation (100-300 mg/day)
- Lipoic acid (300-600 mg/day)
- Thiamine (100-300 mg/day)
- B-complex vitamins
Mitochondrial Protectors:
- MitoQ
- PQQ (pyrroloquinoline quinone)
- Creatine
Symptomatic Treatment:
- Levodopa for PD symptoms
- Physical therapy
- Occupational therapy
Investigational Approaches
Enzyme Activation:
- Small molecules to directly enhance α-KGDH activity
- Allosteric activators under development
- Gene therapy approaches
Substrate Augmentation:
- α-Ketoglutarate supplementation
- Metabolic intermediates
- Anaplerotic agents
Prevention and Risk Reduction
Lifestyle Interventions
Dietary considerations: Ketogenic diet may support mitochondrial function
Exercise: Regular aerobic exercise enhances mitochondrial biogenesis
Sleep: Adequate sleep supports mitochondrial quality control
Stress reduction: Chronic stress impairs mitochondrial functionMonitoring
- Regular metabolic screening for at-risk individuals
- Genetic counseling for families with DLST variants
- Early intervention when dysfunction is detected
Research Priorities
Short-term Goals
Characterize function of GWAS-associated DLST variants
Develop cell-based assays for α-KGDH activity
Identify biomarkers for disease progression
Test existing compounds in model systemsLong-term Goals
Develop potent α-KGDH activators
Achieve targeted gene delivery to neurons
Establish preventive strategies for at-risk individuals
Personalize treatment based on genotypeConclusion
DLST encodes the E2 subunit of α-ketoglutarate dehydrogenase complex, a pivotal enzyme linking TCA cycle function to neuronal survival. GWAS and biochemical studies confirm its role in Parkinson's disease susceptibility and progression. The enzyme's position as a metabolic hub makes it an attractive therapeutic target, though significant work remains to translate these insights into effective treatments.
See Also
- [Genes Directory](/genes/)
- [Proteins Directory](/proteins/)
- [Citric acid cycle mechanisms](/mechanisms/citric-acid-cycle)
- [Mitochondrial energy metabolism](/mechanisms/mitochondrial-energy-metabolism)
External Links
- [NCBI Gene: DLST](https://www.ncbi.nlm.nih.gov/gene/1727)
- [Ensembl: ENSG00000135842](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135842)
- [UniProt: P36957](https://www.uniprot.org/uniprot/P36957)
- [OMIM: 608835](https://www.omim.org/entry/608835)